Immutep Overview

  • Year Founded
  • 1987

Year Founded

  • Status
  • Public

  • Employees
  • 44

Employees

  • Stock Symbol
  • IMM

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.19
  • (As of Friday Closing)

Immutep General Information

Description

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.

Contact Information

Website
www.immutep.com
Formerly Known As
Prima, PBMD, PrimaBioMed, PrimaBio Med, Prima BioMedical, Prima Bio Med, Prima BioMed Ltd., Prima BioMed
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Level 33, Australia Square
  • 264 George Street
  • Sydney, New South Wales 2000
  • Australia
+61 (02)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
ASX
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Level 33, Australia Square
  • 264 George Street
  • Sydney, New South Wales 2000
  • Australia
+61 (02)

Immutep Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Immutep Stock Performance

As of 09-May-2025, Immutep’s stock price is $0.19. Its current market cap is $274M with 1.46B shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.19 $0.19 $0.13 - $0.32 $274M 1.46B 3.17M

Immutep Financials Summary

As of 31-Mar-2025, Immutep has a trailing 12-month revenue of null.

In Thousands,
USD 		TTM 31-Mar-2025 FY 2024 30-Jun-2024 FY 2023 30-Jun-2023 FY 2022 30-Jun-2022
EV 158,052 215,405 140,360 100,353
Revenue 0 0 123
EBITDA (29,036) (26,053) (21,942)
Net Income (27,994) (26,821) (23,342)
Total Assets 134,736 97,601 70,283
Total Debt 1,065 813 1,193
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Immutep Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Immutep‘s full profile, request access.

Request a free trial

Immutep Patents

  • 1

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • Pending

  • Expiring in next 12 mo

Immutep Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
DE-7306548-U Fastening element for two crossing beams Inactive 21-Feb-1973

Immutep Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immutep Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Immutep‘s full profile, request access.

Request a free trial

Immutep Acquisitions (1)

Immutep’s most recent deal was a Merger/Acquisition with Immutep (acquired) for . The deal was made on 17-Dec-2014.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Immutep (acquired) 17-Dec-2014 Merger/Acquisition Biotechnology
To view Immutep’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Immutep ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Immutep’s complete esg history, request access »

Immutep FAQs

  • When was Immutep founded?

    Immutep was founded in 1987.

  • Where is Immutep headquartered?

    Immutep is headquartered in Sydney, Australia.

  • What is the size of Immutep?

    Immutep has 44 total employees.

  • What industry is Immutep in?

    Immutep’s primary industry is Drug Discovery.

  • Is Immutep a private or public company?

    Immutep is a Public company.

  • What is Immutep’s stock symbol?

    The ticker symbol for Immutep is IMM.

  • What is the current stock price of Immutep?

    As of 09-May-2025 the stock price of Immutep is $0.19.

  • What is the current market cap of Immutep?

    The current market capitalization of Immutep is $274M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »